Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Following recent approval of pirfenidone and nintedanib for idiopathic pulmonary fibrosis (IPF), questions arise about the use of these antifibrotics in patients awaiting lung transplantation (LTx). METHODS: Safety and efficacy of antifibrotic drugs in IPF patients undergoing LTx were investigated in a single-centre retrospective cohort analysis. RESULTS: A total of nine patients, receiving antifibrotic therapy for 419 ± 315 days until subsequent LTx, were included. No major side effects were noted. Significant weight loss occurred during antifibrotic treatment (p = 0.0062). FVC tended to stabilize after 12 weeks of treatment in most patients. A moderate decline in FVC, TLC and DLCO was noted during the whole pretransplant time period of antifibrotic therapy. Functional exercise capacity and lung allocation score remained unchanged. No post-operative thoracic wound healing problems, nor severe early anastomotic airway complications were attributable to prior antifibrotic treatment. None of the patients developed chronic lung allograft dysfunction after a median follow-up of 19.8 (11.2-26.5) months; and post-transplant survival was 100% after 1 year and 80% after 2 years. CONCLUSIONS: Antifibrotic drugs can probably be safely administered in IPF patients, possibly attenuating disease progression over time, while awaiting LTx.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although mechanistically anti-fibrotic medications could affect wound healing, recent case series have shown no impaired wound or anastomotic healing and no increase in bleeding risk in patients on these medications.(240, 241)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [240]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“some studies have shown no notable effects of anti-fibrotic agents on wounds, anastomosis, or bleeding [51-53].”
From Indications for Lung Transplantation and Patient Selection (2022) · cites this paper as [53]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005 · cited 1×
“Nintedanib is a tyrosine kinase inhibitor, which blocks receptors for platelet-derived growth factor (PDGF), fibroblast growth factor (FGF), and vascular endothelial growth factor (VEGF), thus inhibiting downstream signaling in (myo-)fibroblasts [10].”
BackgroundDevelopment of the New Lung Allocation System in the United States
Egan, T. M., Murray, S., Bustami, R. T., Shearon, T. H., McCullough, K. P., Edwards, L. B., Coke, M. A., Garrity, E. R., Sweet, S. C., Heiney, D. A., et al. (2006) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2006.01276.x · Cited by 767 · cited 1×
“An average LAS of 32 at the time of LTx in our study may seem fairly low for IPF patients, yet LAS was quite comparable between our treated patients and historical controls; and was in the same range (median of ±35) as previously described for IPF patients at LTx listing [18].”
ResultNoble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468 · cited 3×
“6%pred, which corroborates recent findings that both pirfenidone and nintedanib reduce the proportion of patients with a ≥10% decline in FVC %pred after 1 year of treatment [5, 6].”
MethodResultConte, E., Gili, E., Fagone, E., Fruciano, M., Iemmolo, M., & Vancheri, C. (2014) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2014.02.014 · Cited by 368 · cited 1×
“The antifibrotic properties of pirfenidone result from inhibition of transforming growth factor (TGF)-β expression, thus attenuating myofibroblast differentiation and fibroblast activity [9].”
BackgroundEffect of the lung allocation score on lung transplantation in the United States
Egan, T. M., & Edwards, L. B. (2016) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2016.01.010 · Cited by 270 · cited 1×
“ever, in the last few years, as seen in the US, an increase in LAS is also noted in our centre, with more sicker patients (LAS > 40) being listed for LTx [19].”
Background
Research works printed but not linked: 1
- National Clinical Guideline Centre (UK). Diagnosis and management of suspected idiopathic pulmonary fibrosis: idiopathic pulmonary fibrosis, National Institute for Health and Care Excellence: clinical guidelines. London: Royal College of Physicians (UK); 2013.
Cited by
Leard, L. E., Holm, A. M., Valapour, M., Glanville, A. R., Attawar, S., Aversa, M., Campos, S. V., Christon, L. M., Cypel, M., Dellgren, G., et al. (2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.07.005 · Cited by 821
Lung transplantation for idiopathic pulmonary fibrosis
George, P. M., Patterson, C. M., Reed, A. K., & Thillai, M. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30502-2 · Cited by 297
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017) · European Respiratory Review · doi:10.1183/16000617.0057-2017 · Cited by 295
The therapy of idiopathic pulmonary fibrosis: what is next?
Somogyi, V., Chaudhuri, N., Torrisi, S. E., Kahn, N., Müller, V., & Kreuter, M. (2019) · European Respiratory Review · doi:10.1183/16000617.0021-2019 · Cited by 265
Rivera‐Ortega, P., Hayton, C., Blaikley, J., Leonard, C. T., & Chaudhuri, N. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618800618 · Cited by 90
Metadata
- Authors
- Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R.
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- KU Leuven (BE)
- Corresponding author
- Vos, Robin
- Venue
- BMC Pulmonary Medicine
- Published
- 2016-11-18
- Volume
- 16
- Issue
- 1
- Pages
- 156-156
- ISSN
- 1471-2466 (ISSN-L)
- PMC
- PMC5116160
- OpenAlex
- W2550940244
- Cited by
- 65
- References
- 19
- Citations by year
- 2025: 1 · 2024: 1 · 2023: 8 · 2022: 6 · 2021: 9 · 2020: 3 · 2019: 6 · 2018: 13 · 2017: 18
- FWCI
- 11.02
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- BMC Pulmonary Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Lirias (submittedVersion, cc-by)
- Funders
- Fonds Wetenschappelijk Onderzoek (12G8715N, .0723.10, G.0679.12 and G.0679.12)
- Universitaire Ziekenhuizen Leuven (STG/15/023)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, lung transplantation, antifibrotic agents, pirfenidone, nintedanib, drug safety, forced vital capacity decline, weight loss, chronic lung allograft dysfunction, post-transplant survival, lung allocation score
- MeSH terms
- Aged, Anti-Inflammatory Agents, Non-Steroidal, Belgium, Female, Graft Survival, Humans, Indoles, Lung, Male, Middle Aged, Postoperative Complications, Pyridones, Retrospective Studies, Vital Capacity, Lung Transplantation, Disease Progression, Idiopathic Pulmonary Fibrosis, Tertiary Care Centers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. https://app.cochat.ai/papers/10.1186/s12890-016-0308-z
- The paper
- Delanote, I., Wuyts, W. A., Yserbyt, J., Verbeken, E. K., Verleden, G. M., & Vos, R. (2016). Safety and efficacy of bridging to lung transplantation with antifibrotic drugs in idiopathic pulmonary fibrosis: a case series. BMC Pulmonary Medicine. https://doi.org/10.1186/s12890-016-0308-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.